Direct acting antiviral agents-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study.

Fiche publication


Date publication

septembre 2017

Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent, Dr HABERSETZER François


Tous les auteurs :
Dharancy S, Coilly A, Fougerou-Leurent C, Duvoux C, Kamar N, Leroy V, Tran A, Houssel-Debry P, Canva V, Moreno C, Conti F, Dumortier J, Di Martino V, Radenne S, De Ledinghen V, D'Alteroche L, Silvain C, Besch C, Perré P, Botta-Fridlund D, Francoz C, Habersetzer F, Montialoux H, Abergel A, Debette-Gratien M, Rohel A, Rossignol E, Samuel D, Duclos-Vallée JC, Pageaux GP,

Résumé

HCV infection is associated with reduced patient survival following combined liver-kidney transplantation (LKT). The aim of this study was to assess the efficacy and safety of second generation direct active antiviral (DAAs) in this difficult-to-treat population. The ANRS CO23 CUPILT study is a prospective cohort including transplant recipients with recurrent HCV treated with DAAs. The present work focused on recipients with recurrent HCV following LKT. The study population included 23 patients. All patients received at least one NS5B inhibitor (Sofosbuvir) in their antiviral regimen an average of 90 months after LKT. Ninety six percent of recipients achieved a SVR at week 12 (SVR12). In terms of tolerance, 39% of recipients presented with at least one serious adverse event. None of the patients experienced acute rejection during therapy and there were no deaths during follow-up. The glomerular filtration rate (GFR) decreased significantly from baseline to the end of therapy. However, this study did not show that the decline in GFR persisted over time or that it was directly related to DAAs. The DAAs-based-regimen is well tolerated with excellent results in terms of efficacy. It will become the gold standard for the treatment of recurrent HCV following LKT. This article is protected by copyright. All rights reserved.

Mots clés

clinical research/practice, infection and infectious agents - viral: hepatitis C, infectious disease, kidney failure/injury, kidney transplantation/nephrology, liver disease: infectious, liver transplantation/hepatology

Référence

Am. J. Transplant.. 2017 Sep;: